Protective effect of Picroliv, the active constituent of Picrorhiza kurroa, against chemical carcinogenesis in mice.
Cancer chemoprevention of chemically induced tumours by Picroliv, an iridoid glycoside mixture purified from Picrorhiza kurroa, was studied on 20-methylcholanthrene (20-MC)-induced sarcoma model and 7,12-dimethylbenz[a]anthracene (DMBA)-initiated papilloma formation in BALB/c mice. Administration of Picroliv (100 and 200 mg/kg, p.o) inhibited the sarcoma development by 47 and 53% as estimated on day 200 after 20-MC administration. Control animals started dying of tumour burden 76 days after 20-MC administration and all animals were dead by day 170, while 60 and 66% of the animals survived in the Picroliv treated group, 100 and 200 mg/kg, respectively. Picroliv exhibited anti-tumour-promoting activity on a two-stage carcinogenesis test on mouse skin using DMBA as an initiator and croton oil as a promoter. Topical application of Picroliv (1 and 5 mg/mouse) 30 minutes prior to that of croton oil application resulted in a 50 and 60% reduction in the number of animals that developed papillomas, and 48 and 64% reduction in the number of papillomas per mouse. There was also a delay in the onset of first skin tumour in the group of animals treated with Picroliv. Oral administration of Picroliv (150 mg/kg, p.o.) prior to DMBA application delayed the onset of papillomas and the percent of mice (60%) with tumours indicates that Picroliv inhibited the tumour initiation induced by DMBA. Picroliv administration was also found to increase the life span of transplanted Dalton's Lymphoma Ascites (DLA) and Ehrlich Ascites Carcinoma (EAC) harboring mice and reduced the volume of transplanted solid tumours.
Rajeshkumar
N V
NV
Amala Cancer Research Centre, Thrissur, Kerala, India.
Kuttan
R
R
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D002273:Carcinogens; D002934:Cinnamates / Q000627:therapeutic use*; D003436:Croton Oil / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006027:Glycosides / Q000627:therapeutic use*; D008297:Male; D008748:Methylcholanthrene; D051379:Mice; D008807:Mice, Inbred BALB C; D008956:Models, Chemical; D009369:Neoplasms / Q000139:chemically induced* / Q000517:prevention & control*; D010212:Papilloma / Q000139:chemically induced / Q000517:prevention & control; D010936:Plant Extracts / Q000627:therapeutic use*; D012509:Sarcoma / Q000139:chemically induced / Q000517:prevention & control; D013997:Time Factors; D014641:Vanillic Acid / Q000627:therapeutic use*
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D002934:Cinnamates; D003879:Dermatologic Agents; D006027:Glycosides; D010936:Plant Extracts; C057463:kutkin; D008748:Methylcholanthrene; D015127:9,10-Dimethyl-1,2-benzanthracene; D003436:Croton Oil; D014641:Vanillic Acid